{
    "nct_id": "NCT04585750",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2020-10-14",
    "study_start_date": "2020-10-29",
    "study_completion_date": null,
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: pembrolizumab"
            },
            {
                "drug_name": "Drug: rezatapopt"
            }
        ]
    },
    "long_title": "A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)",
    "last_updated": "2025-10-31",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE1",
    "principal_investigator": "NA",
    "principal_investigator_institution": "PMV Pharmaceuticals, Inc",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [],
    "protocol_no": "",
    "protocol_target_accrual": 300,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria:",
        "* At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval.",
        "* Locally advanced or metastatic solid malignancy with a TP53 Y220C mutation",
        "* Eastern Cooperative Oncology Group (ECOG) status of 0 or 1",
        "* Previously treated with one or more lines of anticancer therapy and progressive disease",
        "* Adequate organ function",
        "* Measurable disease per RECIST v1.1 (Phase 2)",
        "Additional Criteria for Inclusion in Phase 1b (rezatapopt) + pembrolizumab combination)",
        "* Anti-PD-1/PD-L1 naive or must have progressed on treatment",
        "* Measurable disease",
        "Exclude - Exclusion Criteria:",
        "Exclude - * Anti-cancer therapy within 21 days (or 5 half-lives) of receiving the study drug",
        "Exclude - * Radiotherapy within 14 days of receiving the study drug",
        "Exclude - * Primary CNS tumor",
        "Exclude - * History of leptomeningeal disease or spinal cord compression",
        "Exclude - * Brain metastases, unless neurologically stable and do not require steroids to treat associated neurological symptoms",
        "Exclude - * Stroke or transient ischemic attack within 6 months prior to screening",
        "Exclude - * Heart conditions such as unstable angina within 6 months prior to screening, uncontrolled hypertension, a heart attack within 6 months prior to screening, congestive heart failure, prolongation of QT interval, or other rhythm abnormalities",
        "Exclude - * Strong CYP3A4 inducers and strong CYP2C9 inhibitors/inducers within 14 days of first dose of rezatapopt",
        "Exclude - * History of gastrointestinal (GI) disease that may interfere with absorption of study drug or patients unable to take oral medication",
        "Exclude - * History of prior organ transplant",
        "Exclude - * Known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer",
        "Exclude - * Known, active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection",
        "Exclude - Additional Criteria for Exclusion from Phase 2 (rezatapopt monotherapy)",
        "Exclude - * Known KRAS mutation, defined as a single nucleotide variant (SNV) (Phase 2)",
        "Exclude - Additional Criteria for Exclusion from Phase 1b (rezatapopt) + pembrolizumab combination)",
        "Exclude - * Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and discontinued from that treatment due to a Grade 3 or higher immune-related AE (irAE)",
        "Exclude - * Received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention",
        "Exclude - * Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy within 7 days prior to the first dose of study drug",
        "Exclude - * Hypersensitivity (\u2265 Grade 3) to pembrolizumab and/or any of its excipients",
        "Exclude - * Active autoimmune disease that has required systemic treatment in past 2 years",
        "Exclude - * History of radiation pneumonitis",
        "Exclude - * History of (non-infectious) or active pneumonitis / interstitial lung disease that required steroids",
        "Exclude - * Active infection requiring systemic therapy",
        "Exclude - * Known history of HIV infection",
        "Exclude - * Has previously received rezatapopt"
    ],
    "short_title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "PMV Pharmaceuticals, Inc",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "Phase 1 Monotherapy Dose Escalation",
                        "arm_internal_id": 0,
                        "arm_description": "Multiple dose levels of daily oral rezatapopt will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of rezatapopt to recommend a Phase 2 dose (RP2D).",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: rezatapopt",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Phase 1b Combination Therapy Dose Escalation, Part 1",
                        "arm_internal_id": 1,
                        "arm_description": "Multiple dose levels of daily oral rezatapopt in combination with a stable dose of pembrolizumab (200 mg IV q3 weeks) will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 to recommend a Phase 2 dose (RP2D) of rezatapopt when administered in combination with pembrolizumab.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: rezatapopt",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: pembrolizumab",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Phase 1b Combination Therapy Dose Expansion, PD(L)-1 naive patients",
                        "arm_internal_id": 2,
                        "arm_description": "Additional (expansion of) participants will enroll at the RP2D of daily oral PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 naive patients.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: rezatapopt",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: pembrolizumab",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Phase 1b Combination Therapy Dose Expansion, PD(L)-1 relapsed/refractory patients",
                        "arm_internal_id": 3,
                        "arm_description": "Additional (expansion of) participants will enroll at the RP2D of daily oral rezatapopt when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 relapsed/refractory patients.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: rezatapopt",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: pembrolizumab",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Phase 2 Monotherapy Dose Expansion, Ovarian Cancer Cohort",
                        "arm_internal_id": 4,
                        "arm_description": "Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Ovarian Cancer Cohort participants will have locally advanced or metastatic ovarian cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: rezatapopt",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Phase 2 Monotherapy Dose Expansion, Lung Cancer Cohort",
                        "arm_internal_id": 5,
                        "arm_description": "Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Lung Cancer Cohort participants will have locally advanced or metastatic lung cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: rezatapopt",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Phase 2 Monotherapy Dose Expansion, Breast Cancer Cohort",
                        "arm_internal_id": 6,
                        "arm_description": "Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Breast Cancer Cohort participants will have locally advanced or metastatic breast cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: rezatapopt",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Phase 2 Monotherapy Dose Expansion, Endometrial Cancer Cohort",
                        "arm_internal_id": 7,
                        "arm_description": "Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Endometrial Cancer Cohort participants will have locally advanced or metastatic endometrial cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: rezatapopt",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Phase 2 Monotherapy Dose Expansion, Other Solid Tumors Cohort",
                        "arm_internal_id": 8,
                        "arm_description": "Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Other Solid Tumors Cohort participants will have locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: rezatapopt",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "and": [
                                    {
                                        "or": [
                                            {
                                                "clinical": {
                                                    "oncotree_primary_diagnosis": "_SOLID_"
                                                }
                                            },
                                            {
                                                "clinical": {
                                                    "oncotree_primary_diagnosis": "_LIQUID_"
                                                }
                                            }
                                        ]
                                    },
                                    {
                                        "clinical": {
                                            "age_numerical": ">=12",
                                            "disease_status": [
                                                "Locally Advanced",
                                                "Metastatic"
                                            ]
                                        }
                                    }
                                ]
                            },
                            {
                                "and": [
                                    {
                                        "genomic": {
                                            "hugo_symbol": "TP53",
                                            "variant_category": "Mutation",
                                            "protein_change": "p.Y220C"
                                        }
                                    },
                                    {
                                        "genomic": {
                                            "hugo_symbol": "KRAS",
                                            "variant_category": "!Mutation"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        ]
    }
}